Tu'uhevaha Kaitu'u-Lino
0000-0001-6233-9737
University of Padova
81 papers found
Refreshing results…
Placental-specific sFLT-1: role in pre-eclamptic pathophysiology and its translational possibilities for clinical prediction and diagnosis
Epidermal Growth Factor Rescues Endothelial Dysfunction in Primary Human Tissues In Vitro
Nuclear factor of activated T-cells (NFAT) regulates soluble fms-like tyrosine kinase-1 secretion (sFlt-1) from human placenta
Steroid sulfatase is increased in the placentas and whole blood of women with early-onset preeclampsia
ATF3 is a negative regulator of inflammation in human fetal membranes
Placental Growth Factor Is Secreted by the Human Endometrium and Has Potential Important Functions during Embryo Development and Implantation
A comparison of sample collection methods for quantifying cell-free fetal neurodevelopment transcripts in amniotic fluid
Effects of simvastatin, rosuvastatin and pravastatin on soluble fms-like tyrosine kinase 1 (sFlt-1) and soluble endoglin (sENG) secretion from human umbilical vein endothelial cells, primary trophoblast cells and placenta
Maternal plasma concentrations of the placental specific sFLT-1 variant, sFLT-1 e15a, in fetal growth restriction and preeclampsia
Variable effect of maternal oral glucose load on circulating cell-free placental mRNAs
Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction
Loss of Akt increases soluble endoglin release from endothelial cells but not placenta
Jumonji Domain Containing Protein 6 Is Decreased in Human Preeclamptic Placentas and Regulates sFLT-1 Splice Variant Production1
Identifying late onset fetal growth restriction by measuring circulating placental RNA in the maternal blood at 28 weeks gestation
Heme Oxygenase-1 Is Not Decreased in Preeclamptic Placenta and Does Not Negatively Regulate Placental Soluble fms-Like Tyrosine Kinase-1 or Soluble Endoglin Secretion
A wash step at collection of placental biopsies from preeclamptic pregnancies does not adversely affect levels of sFlt-1 or endoglin
YC-1 reduces placental sFlt-1 and soluble endoglin production and decreases endothelial dysfunction: A possible therapeutic for preeclampsia
Effects of Pravastatin on Human Placenta, Endothelium, and Women With Severe Preeclampsia
Transcription factors E2F1 and E2F3 are expressed in placenta but do not regulate MMP14
Human HtrA4 Expression Is Restricted to the Placenta, Is Significantly Up-Regulated in Early-Onset Preeclampsia, and High Levels of HtrA4 Cause Endothelial Dysfunction
Missing publications? Search for publications with a matching author name.